天康生物
(002100)
| 流通市值：92.15亿 | | | 总市值：92.15亿 |
| 流通股本：13.65亿 | | | 总股本：13.65亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 14,705,995,884.82 | 8,963,149,801.46 | 3,890,843,979.48 | 16,731,607,636.11 |
| 营业收入 | 14,705,995,884.82 | 8,963,149,801.46 | 3,890,843,979.48 | 16,731,607,636.11 |
| 二、营业总成本 | 15,185,082,263.25 | 9,367,051,782.51 | 3,865,300,990.35 | 16,354,974,656.81 |
| 营业成本 | 14,102,713,411.33 | 8,673,203,407.28 | 3,549,707,162.09 | 14,974,833,459.82 |
| 税金及附加 | 33,248,413.27 | 21,117,941.64 | 9,863,979.35 | 39,208,956.26 |
| 销售费用 | 390,582,458.45 | 249,046,818.36 | 106,983,141.48 | 475,205,826.38 |
| 管理费用 | 323,158,998.31 | 218,252,469.31 | 104,830,863.2 | 476,877,832.23 |
| 研发费用 | 178,179,797.12 | 98,737,400.7 | 40,156,984.48 | 181,061,744.95 |
| 财务费用 | 157,199,184.77 | 106,693,745.22 | 53,758,859.75 | 207,786,837.17 |
| 其中:利息费用 | 199,671,196.92 | 139,179,255.51 | 70,835,550.29 | 242,993,618.82 |
| 其中:利息收入 | 44,012,171.9 | 30,063,007.84 | 15,057,085.67 | 37,707,817.6 |
| 加:公允价值变动收益 | -12,170 | -122,110 | 15,270 | - |
| 加:投资收益 | 3,557,400.48 | 1,529,523.04 | 1,139,551.82 | 17,082,869.74 |
| 资产处置收益 | 5,989,878.76 | -5,332,481.88 | -2,711,470.56 | -28,982,363.01 |
| 资产减值损失(新) | -49,364,048.98 | -47,383,933.55 | - | -106,616,858.94 |
| 信用减值损失(新) | -50,654,794.28 | -40,164,295.23 | -21,500,860.35 | -45,725,799.13 |
| 其他收益 | 36,053,238.87 | 13,229,810.37 | 8,345,527.01 | 64,219,453.02 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -533,516,873.58 | -482,145,468.3 | 10,831,007.05 | 276,610,280.98 |
| 加:营业外收入 | 1,648,191.31 | 498,164.59 | 262,711.97 | 1,679,383.99 |
| 减:营业外支出 | 35,321,148.28 | 16,875,435.01 | 7,142,300.5 | 42,448,185.29 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -567,189,830.55 | -498,522,738.72 | 3,951,418.52 | 235,841,479.68 |
| 减:所得税费用 | 21,611,408.89 | 21,841,669.65 | 21,100,463.83 | 21,696,308.91 |
| 六、净利润 | -588,801,239.44 | -520,364,408.37 | -17,149,045.31 | 214,145,170.77 |
| 持续经营净利润 | -588,801,239.44 | -520,364,408.37 | -17,149,045.31 | 214,145,170.77 |
| 归属于母公司股东的净利润 | -504,382,106.12 | -447,288,636.14 | -14,282,251.76 | 301,548,661.86 |
| 少数股东损益 | -84,419,133.32 | -73,075,772.23 | -2,866,793.55 | -87,403,491.09 |
| (一)基本每股收益 | -0.37 | -0.33 | -0.01 | 0.22 |
| (二)稀释每股收益 | -0.37 | -0.33 | -0.01 | 0.22 |
| 八、其他综合收益 | 2,814,083.83 | 22,490,620.31 | 9,848,219.07 | 10,794,115.87 |
| 归属于母公司股东的其他综合收益 | 3,095,526.61 | 21,100,559.69 | 9,848,219.07 | 10,592,956.72 |
| 九、综合收益总额 | -585,987,155.61 | -497,873,788.06 | -7,300,826.24 | 224,939,286.64 |
| 归属于母公司股东的综合收益总额 | -501,286,579.51 | -426,188,076.45 | -4,434,032.69 | 312,141,618.58 |
| 归属于少数股东的综合收益总额 | -84,700,576.1 | -71,685,711.61 | -2,866,793.55 | -87,202,331.94 |
| 公告日期 | 2023-10-31 | 2023-08-26 | 2023-04-29 | 2023-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |